Martin Stapleton is the Chairman of Libero Pharma and led the acquisition of Libero’s IP and fund raising.  Martin has been building technology companies across the world for the past 30 years, both as an investor and a board member.  Martin has run several technology funds (RVC, Sofius and Ipex Capital) and in more recent years has been a provider of entrepreneurial capital to promising technology companies.  Martin is also Chairman of PlaqueTec Ltd, the cardiovascular biomarker discovery company.

Over the past three decades, Andrew has built a successful career in the pharmaceutical industry having held senior commercial positions in both large and small life science organisations including Syntropharma, Pharmacia and ProStrakan. The combination of his commercial and R&D experience has enabled him to develop, and launch, numerous, well-differentiated products to global audiences.

As Chief Executive Officer (and a founding director) Andrew is responsible for all operational matters.

Following clinical practice in medicine and surgery, Simon joined industry in 2010. He has built up drug development expertise across all stages of the life-cycle from pre-clinical testing to commercial launch. His experience incorporates leadership roles covering numerous therapy areas at companies of varying size, including Amgen and UCB. Simon is primarily responsible for Libero’s clinical development program and R&D collaborations. He is a member of both the faculty of pharmaceutical medicine and royal college of surgeons.